NCT03845140View on ClinicalTrials.gov

L-PZQ ODT in Schistosoma Infected Children

PHASE3CompletedINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

October 11, 2021

Study Completion Date

October 11, 2021

Conditions
Schistosomiasis
Interventions
DRUG

L-PZQ ODT 50 mg/kg

Participants received single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.

DRUG

Biltricide®

Participants received single oral dose of Biltricide® 40 mg/kg on Day 1.

DRUG

L-PZQ ODT 60 mg/kg

Participant received single oral dose of L-PZQ ODT 60 mg/kg on Day 1.

Trial Locations (2)

40100

Kemri Kisumu, Kisumu

22BP770

Universitè de Cocody, Abidjan

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03845140 - L-PZQ ODT in Schistosoma Infected Children | Biotech Hunter | Biotech Hunter